| |
|
|
|
|
|
|
Bone and Tooth Society Annual MeetingBirmingham, UK Exhibitors and Other Supporters
Eli Lilly and Company is one of the world's largest research-based pharmaceutical companies, dedicated to creating and delivering innovative pharmaceutical healthcare solutions that enable people to live longer, healthier and more active lives. Our research and development efforts constantly strive to address urgent unmet medical needs in several therapeutic areas. Eli Lilly and Company was founded in 1876 in Indianapolis, USA, and has had a long history of producing endocrine products, dating all the way back to the collaboration with Banting and Best and the introduction of the world's first insulin product in 1922. To assist in the therapeutic management of Osteoporosis, Lilly has two
products each catering for different patient needs, - Raloxifene can
be used in the early post menopausal stage, whilst Teriparatide was recently
launched for the treatment of severe osteoporosis. Merck Sharp and Dohme Limited (MSD) is the UK subsidiary of Merck & Co., Roche and GlaxoSmithKline Roche is one of the world's leading research-based healthcare groups. With the aim of enhancing people's health and quality of life, our core businesses in pharmaceuticals and diagnostics provide innovative products and services for the prevention, diagnosis and treatment of disease. In the UK, Roche employs around 1,800 people in prescription and over the counter medicines and diagnostics. Together, our businesses in the UK strive to make a real difference to healthcare, the UK's health services and, most importantly, people's lives. GSK, one of the world's leading
research-based pharmaceutical and healthcare companies, is committed
to improving the quality of
human life by enabling
people to do more, feel better and live longer. Servier is France's leading independent pharmaceutical company, with a tradition of ground-breaking research. In 2002 Servier was awarded the Prix Galien in recognition of the "quantity, quality and dynamism" of research in major fields of medicine, such as cardiovascular disease, psychiatric and CNS disorders, cancer treatment, diabetes, gynaecology and rheumatology. Servier has turned its attention to osteoporosis research in the firm belief that real progress in this field depends on a new understanding of the process of bone physiology. We believe that our research today will help reduce the fractures of
tomorrow. Founded in 1986, Shire Pharmaceuticals Group plc is a global specialty pharmaceutical company whose mission is to develop and market medicines that improve the quality of life for patients and their caregivers. With an international presence in the main European markets and the
USA, Shire is now the UK's third largest pharmaceutical company and one
of the fastest growing specialty companies in the world. In the UK, Shire's
main products include Calcichew D3 Forte (calcium & vitamin D deficiency
and an adjunct in osteoporosis treatment) and Colazide (ulcerative colitis)
in the UK, and Adderall XL (attention deficit hyperactivity disorder)
in the USA. The Clinical Endocrinology Trust was established some years ago by Blackwells, using funds derived from the profits of Clinical Endocrinology, which is one of their most successful journals. The Trust’s aim is to benefit endocrinology and endocrinologists. Aside from the provision of student grants, the Trust offers support in many ways. The Clinical Endocrinology Trust/RSM Visiting Professor tours the UK for up to 14 days prior to the BES meeting each year, speaking at various endocrine departments before lecturing at the BES itself. The separately funded Clinical Endocrinology Trust Lecturer also delivers a lecture at the BES meeting. The Trust provides further support to the BES in the form of travel grants for young endocrinologists who wish to attend the meeting. This year, the BES meeting will also feature a Clinical Endocrinology Trust Symposium, supported by a contribution of £4000. A small amount of money is given out to individual travel/study grants each year, and the Trust and the Society for Endocrinology support a shared research fellowship. The Clinical Endocrinology Trust also gives a small prize for the best case presentation at the Clinical Group meeting previously held at the RSM, and supplies subscriptions to Clinical Endocrinology to Eastern European countries. Overall it is anticipated that donations this year will amount to around £60,000. The present Chairman is Professor Lesley Rees, and the other trustees
are Professors Steve Franks, Peter Baylis and Mike Sheppard, with Lesley
Whelan from Blackwells. We are open to suggestions for other ways in
which endocrinology can be supported. Galen Limited is a privately owned pharmaceutical sales and marketing company established in 1968. Based in Craigavon (Northern Ireland) Galen promotes branded and generic prescription medicines in the United Kingdom and Ireland, with major brands in key therapeutic areas, particularly women's health, urology and pain management. In April 2004 the company was acquired by Dr. Allen McClay, the original
founder of Galen and the owner of a group of pharmaceutical services
companies under the umbrella of
Almac Sciences. With access to the wide variety of services, which range
from drug
discovery through clinical trials' management to commercial manufacture,
Galen is now
well placed to fulfill our vision of creating an international pharmaceutical
company from its
base in Northern Ireland. Key to achieving this vision will be developing
our core values of Gresham Scientific Instruments Gresham Scientific Instruments Ltd are the official distributors for SkyScan NV, a European manufacturer of laboratory x-ray micro-tomography systems providing 3-dimensional in-vivo and in-vitro imaging of bone and soft tissues with micron-level resolution. Micro-CT scanning results in a sequence of high resolution cross-sectional images from which both 2D and 3D morphological information may be derived. A pertinent example is the ability to extract typical ASBMR-defined parameters for trabecular bone. By the use of surface rendering techniques, stunning 3-dimensional models can be produced from the cross-sectional image dataset. Many examples are available to view. Immunodiagnostic Systems (IDS) offers a range of esoteric immunoassay kits for clinical and research use. The company focuses in Bone & Mineral Metabolism and Growth Factor research, and engages in collaborative projects with researchers worldwide. IDS is a leader in the field of Vitamin D analysis, offering both manual
and automated 25(OH) Vitamin D methods, an award-winning 1,25-Dihydroxy
Vitamin D RIA system, and now announces OCTEIA 1,25(OH)2 Vitamin D, an
EIA employing the proven immunocapsule sample preparation. IDS OsteoSite™ antibodies include multiple forms of PTHrp, Cathepsin K, Osteoarthritis Matrix Antigen (a Collagen VI epitope) and a specific Osteoclast Antigen; the GroPep range has multi-species Growth Factor and GF-Binding Protein antibodies; and the Eurodiagnostica range has antibodies to many matrix antigens, neuropeptides and associated reagents. Dentine discs are available for osteoclast activity studies in vitro,
suitable for use in microtitre wells. Oxford Biosystems, in various forms, has been trading for over ten years, initially as Metra Biosystems and then later as Quidel Diagnostics UK Ltd. The company has kept its key personnel throughout the ten years and has strived to provide speciality diagnostic kits for research, early clinical and routine clinical use. We currently represent 16 companies from Europe and USA and provide
diagnostic kits for:
Androgen Assessment, Anaemia Markers, Angiogenic Factors, Biogenic Amines,
Bone& Mineral Metabolism, Oncology, Cardiovascular & Renal,
Cytokines, Diabetes, Eicosanoids,
Fertility & Reproduction, Growth, Mineral/Salt Balance, Thyroid Function,
Gastroenterology/Nutrition, Immunology, Anti-ageing/Preventive Medicine,
Animal Hormones,
and Research Antibodies etc. The majority of these kits are provided
in the ELISA, IRMA and
RIA format. Pfizer, with its UK business headquarters in Surrey and global headquarters in New York, is a research-based global pharmaceutical company. Pfizer discovers, develops, manufactures and markets leading prescription medicines for humans and animals, and many of the world's best-known consumer treatments. In 2003, Pfizer's net contribution to UK Government was over £190 million; with a research and development spend of over £600 million. Every month, over two million patients in the UK are prescribed a Pfizer
medicine. It is estimated that on any given day, 40 million people
around the world are treated with a Pfizer medicine. Technoclone Ltd is the exclusive distributor in the UK and Ireland of the Metra® range of Bone Marker assay kits from Quidel Corporation, global leader in bone health assays. The current Metra® range of ELISA assays includes a highly specific Bone Alkaline Phosphatase (BAP) assay, serum Osteocalcin, Collagen Type -1 C-Terminal propeptide (CICP), DPD and Total DPD, PYD, alpha-1 Helical Peptide and YKL-40, as well as a chromogenic Creatinine assay and other research reagents. Quidel will also be introducing new Metra kits for TRAcP 5b and Osteoprotegerin in August 2005, which will be the first of a range of new bone health assays including rapid point-of-care tests to be introduced in the near future. Technoclone also markets an extensive range of autoimmune assays, complement
diagnostics and research reagents and multiplex cytokine assays. The Alliance for Better Bone Health
|
|
|||||||||||||||
|
||||||||||||||||||
